Report me for selling fake medicine? Why are you crying when your illness relapses?

……

Chen Xuan tapped the table lightly with his hand and fell into thought.

He has to consider the cost-effectiveness of the cooperation.

If the specific drug for lung cancer successfully enters the Chinese market, then there will be no need to worry about the Chinese market.

However, the international market is the weak point of Antai Pharmaceutical Group. Without any sales channels, rebuilding it will be the biggest challenge.

In addition, Antai Pharmaceutical Group does not have any connections abroad, and the drug certification in various countries alone is already a huge problem.

In addition to passing clinical trials in the country, certain procedures are also required for listing overseas.

Similarly, new drugs from other countries entering the Chinese market also need to pass clinical trials before they can be approved for marketing, but the procedures are simpler.

As for how long this recognition process will take, it mainly depends on the strength and connections of the pharmaceutical company.

The stronger the pharmaceutical company is and the wider its network of contacts, the faster it will pass local drug certification; otherwise, it will be delayed for a long time.

There is no doubt that Antai Pharmaceutical Group has no foundation in this regard. Drug certification in various countries is already a major problem, and the subsequent distribution and sales is another difficulty.

Therefore, Chen Xuan has to consider this issue and also consider whether cooperation with Novartis can solve this problem.

Novartis is one of the top ten pharmaceutical giants in the world.

In this regard, its capabilities are definitely more than ten times stronger than those of Antai Pharmaceutical Group.

If Novartis is truly sincere in helping solve the problem, then it can indeed help its lung cancer drug open up overseas markets at the fastest speed.

There is no doubt about this.

And if Novartis becomes the agent, maybe we can sell a million boxes in the first year.

But if Antai Pharmaceutical Group distributes the product itself, it may not even sell 10 boxes in the first year, or even worse, it may not even be approved for marketing.

"Yes, I also hope for win-win cooperation!"

After careful consideration, Chen Xuan finally made this decision.

In the Chinese market, Antai Pharmaceutical Group has no problems.

Whether it is collection or individual sales, it can be easily done.

With the country's protection, all problems will no longer be problems.

But it is different in overseas markets. When Chinese companies step out of the domestic market and move towards the international market, the challenges they face are terrifying.

No matter how powerful the lung cancer drug is, patients need this life-saving drug very much.

But as long as the issue is not resolved, overseas dignitaries will not be able to enter the local market.

For these people, what does the life or death of the patient have to do with them?

What matters is always self-interest.

Even if they need this medicine themselves, they can get it through various methods. At worst, they can come to China to buy it directly, and they don’t have to wait like ordinary people.

Therefore, these overseas dignitaries can restrict this drug without any psychological burden.

As long as they can't make a profit, they won't let it go public.

But with Novartis, there is no need to worry about this situation.

Novartis’ sales channels are very mature, it is very familiar with dignitaries in various countries, and it has a complete industrial chain.

In this case, Novartis can quickly pass local drug certification and complete distribution quickly, saving a lot of time.

Of course, it’s not impossible for Chen Xuan to cooperate with other pharmaceutical companies, as other pharmaceutical companies also have the ability to do so.

For example, AbbVie.

But he is relatively familiar with Novartis, and coupled with the previous cooperation experience, it is better to do business with the familiar one, so there is no need to seek cooperation with other pharmaceutical companies.

"We hope to fully cooperate with Novartis."

"But at the same time, we also hope to add some time limits to the cooperation agreement."

"It would be better for both of us to have these details as detailed as possible, and it would be more convenient for long-term cooperation in the future."